Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells

Journal of Nuclear Medicine

Volumn 43, Issue 9, 2002, Pages 1210-1217

  Rasey, Janet S ^a   Grierson, John R ^a   Wiens, Linda W ^a   Kolb, Pamella D ^a   Schwartz, Jeffrey L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

18F; Cell proliferation; Fluorothymidine; Thymidine kinase; Tumors

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; CELL DNA; DEOXYGLUCOSE C 14; PROTEIN P53; THYMIDINE KINASE; THYMIDINE KINASE 1; TRACER; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; CORRELATION FUNCTION; CULTURE MEDIUM; CYTOSOL; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRRADIATION; LUNG ADENOCARCINOMA; MITOSIS INHIBITION; MITOSIS RATE; PREDICTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WART VIRUS;

ADENOCARCINOMA; CELL CYCLE; CELL DIVISION; CULTURE MEDIA; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HUMANS; LUNG NEOPLASMS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0036732034     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 11C]thymidine in patients with squamous cell carcinoma of the head and neck
2. 2-[C-11]Thymidine imaging of malignant brain tumors
3. Carbon-11-thymidine and FDG to measure therapy response
4. Positron emission tomography in oncology
5. 11C]thymidine PET imaging studies: Validation studies
6. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds
7. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging
8. 11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET
9. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-l-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells
10. 124I]iododeoxyuridine
11. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
12. An improved synthesis of [F-18]FLT
13. Basis of FLT as a cell proliferation marker: Comparative uptake studies with [H-3]thymidine and [H-3]arabinothymidine, and cell analysis in 22 asynchronously growing tumor cell lines
14. Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3′-deoxy-3′-fluorothymidine in comparison to 3′-azido-3′-deoxythymidine
15. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine
16. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials
17. 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS
18. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs
19. 3′-Deoxy-3′-fluorothymidine, a new selective inhibitor of DNA synthesis
20. Human thymidine kinase 1: Regulation in normal and malignant cells
21. Regulation of human thymidine kinase during the cell cycle
22. [F-18]fluorothymidine PET imaging of non-small cell lung cancer (NSCLC): Comparison to Ki-67 proliferation index [abstract]
23. Use of [F-18]FLT for breast cancer imaging
24. Use of [F-18]FLT for imaging gastrointestinal tumors
25. Imaging cellular proliferation as a measure of response to therapy
26. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
27. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 check-point-competent cells
28. Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle
29. Cell-free synthesis of enzymatically active vaccinia virus thymidine kinase
30. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma
31. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients
32. Multiparametric prognostic evaluation of biological factors in primary breast cancer
33. Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung
34. Tumour markers as prognostic aids in prostatic carcinoma
35. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer
36. Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (GO) cells
37. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity
38. Carboxy-terminal residues of mouse thymidine kinase are essential for rapid degradation in quiescent cells
39. Enhanced expression of thymidine kinase in human cells following ionizing radiation
40. 3H]thymidine, and gallium-67